Search
BT200
go.drugbank.com/drugs/DB18333Investigational[A261491] It is under investigation for the treatment of von Willebrand disease and hemophilia A.[L48156] … BT200 (Rondoraptivon pegol) is a PEGylated anti-von Willebrand factor (VWF) aptamer targeted against the VWF A1 domain.
SAR421869
go.drugbank.com/drugs/DB17909InvestigationalSAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.
Inositol 1,3-bisphosphate
go.drugbank.com/drugs/DB02942ExperimentalIt is an experimental compound with no approved therapeutic indications. … The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural
GT-AS
go.drugbank.com/drugs/DB17883ExperimentalGT-AS recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP.
Flunoxaprofen
go.drugbank.com/drugs/DB13317ExperimentalCategories: Antiinflammatory Products for Vaginal Administration, Analgesics, Non-NarcoticTelapristone acetate
go.drugbank.com/drugs/DB05253InvestigationalTelapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.
Mevidalen
go.drugbank.com/drugs/DB19034InvestigationalMevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or
Elinogrel
go.drugbank.com/drugs/DB06350InvestigationalA P2Y12 inhibitor and platelet aggregation inhibitor.
Luseogliflozin
go.drugbank.com/drugs/DB12214InvestigationalLuseogliflozin has been used in trials studying the treatment of Diabetes Melltius, Type 2.
Categories: Drugs Used in DiabetesRO7300490
go.drugbank.com/drugs/DB17535InvestigationalRO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in … RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.
Synonyms: RO 7300490, RO-7300490